الفهرس 
Acknowledgment
EPIDEMIOLOGYOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
This retrospective study was performed to analyze the prognostic factors affecting survival of patients diagnosed with advanced non-small cell lung cancer (NSCLC) in Clinical Oncology department, Assiut University Hospital between 2009 and 2014.
We identified 69 patients with advanced NSCLC. The mean age was 57.67 years. There were 43 males (62.3%) and 26 females (37.7%). The Eastern Cooperative Oncology group performance status (PS) 0 was identified in 17 patients (24.6%) and PS 1 and 2 were identified in 24 (42%) and 23 (33.3%) patients respectively. Forty patients (58%) were smokers. The majority of the patients had adeenocarcinoma (60.9%) as a histological subtype and 17 patients (24.6%) had squamous ell carcinoma.
The stage of the disease according to the American joint Committee on Cancer (AJCC) was as follow: stage IIIA 9 (13%), stage IIIB 22 (31.9%) and stage IV 38 (55.1%). The initial treatment modality (first-line therapy) was chemotherapy in 43 patients (57.71%) and concurrent chemoradiation (CRT) in 17 patients (28.97%). 9 patients (13%) received no treatment (best supportive care).
In univariate analysis; female patients (p=0.04), PS 0 (p=0.001), never smoking (p=0.001), stage IIIA (p=0.008) and concurrent CRT (p=0.001) had better overall survival (OS).
In multivariate analysis, PS (p=.001), stage (p=.001) and type of initial treatment (p=.019) were determined as the independent prognostic factors affecting survival.